Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Blood Advances|January 28, 2020
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysisArianna Masciulli, Alberto Ferrari, Alessandra Carobbio, et al.
Blood Advances|June 9, 2019
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysisAlessandra Carobbio, Alberto Ferrari, Arianna Masciulli, et al.
European Journal of Haematology|November 2, 2020
Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative NeoplasmsAlberto Ferrari, Joseph Scandura, Arianna Masciulli, et al.
Thrombosis|November 16, 2011
The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia VeraRoberto Marchioli, Guido Finazzi, Giorgina Specchia, et al.
Haematologica|May 25, 2019
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysisAlberto Ferrari, Alessandra Carobbio, Arianna Masciulli, et al.
American Journal of Hematology|July 13, 2017
A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched studyTiziano Barbui, Alessandro Maria Vannucchi, Guido Finazzi, et al.
Purinergic Signalling|April 12, 2008
Guanosine effect on cholesterol efflux and apolipoprotein E expression in astrocytesPatrizia Ballerini, Renata Ciccarelli, Patrizia Di Iorio, et al.
Blood Cancer Journal|February 11, 2022
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia veraAlessandra Carobbio, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Leukemia & Lymphoma|November 11, 2016
The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohortsRobyn Marie Scherber, Holly Lynn Geyer, Amylou C Dueck, et al.
Assistenza Infermieristica E Ricerca : AIR|June 3, 2010
[Memorandum for the management of clinical trials]Miriam Valentini, Maria Celeste Pirozzoli, Daniela D'Alonzo, et al.
Pageof 4